Jenburkt Pharmaceuticals (BOM:524731) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524731 Jenburkt Pharmaceuticals Ltd BOM:524731
83 GF Score
Price ₹1,006.70
GF Value ₹1,148.95
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Jenburkt Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Jenburkt Pharmaceuticals Quality Rank Related Terms

BOM:524731
83GF Score
Jenburkt Pharmaceuticals Ltd BOM:524731
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jenburkt Pharmaceuticals (BOM:524731) Overvalued in 2026?

Based on GuruFocus' analysis, Jenburkt Pharmaceuticals stock appears to be undervalued. The current stock price of ₹1,006.70 is trading 12.4% below its estimated GF Value™ of ₹1,148.95. GuruFocus considers Jenburkt Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BOM:524731:

  • Quality Rank:
  • GF Value™: ₹1,148.95 vs. price of ₹1,006.70 (12.4% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the BOM:524731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jenburkt Pharmaceuticals Business Description

Other Exchanges JENBURPH:India
Address 93, Jayprakash Road, Nirmala Apartments, Andheri (West, Mumbai, MH, IND, 400058
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.
83GF Score

Get the complete analysis for BOM:524731

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,006.70
Price
₹1,148.95
GF Value